Abstract. Epithelial-mesenchymal transition (EMT) plays a critical role in embryonic development, wound healing, tissue regeneration, cancer progression and organ fibrosis. The proximal tubular epithelial cells undergo EMT, resulting in matrix-producing fibroblasts and thereby contribute to the pathogenesis of renal fibrosis. The profibrotic cytokine, TGF-β, is now recognized as the main pathogenic driver that has been shown to induce EMT in tubular epithelial cells. Increasing evidence indicate that HIPK2 dysfunction may play a role in fibroblasts behavior, and therefore, HIPK2 may be considered as a novel potential target for anti-fibrosis therapy. Recently, members of the miR-200 family (miR-200a, b and c and miR-141) have been shown to inhibit EMT. However, the steps of the multifactorial renal fibrosis progression that these miRNAs regulate, particularly miR-141, are unclear. To study the functional importance of miR-141 in EMT, a well-established in vitro EMT assay was used to demonstrate renal tubulointerstitial fibrosis; transforming growth factor-β1-induced EMT in HK-2 cells. Overexpression of miR-141 in HK-2 cells, either with or without TGF-β1 treatment, hindered EMT by enhancing E-cadherin and decreasing vimentin and fibroblast-specific protein 1 expression. miR-141 expression was repressed during EMT in a dose-and time-dependent manner through upregulation of HIPK2 expression. Ectopic expression of HIPK2 promoted EMT by decreasing E-cadherin. Furthermore, co-transfection of miR-141 with the HIPK2 ORF clone partially inhibited EMT by restoring E-cadherin expression. miR-141 downregulated the expression of HIPK2 via direct interaction with the 3'-untranslated region of HIPK2. Taken together, these findings aid in the understanding of the role and mechanism of miR-141 in regulating renal fibrosis via the TGF-β1/miR-141/HIPK2/EMT axis, and miR-141 may represent novel biomarkers and therapeutic targets in the treatment of renal fibrosis.
Introduction
Renal fibrosis is the frequent final outcome of a wide variety of progressive chronic kidney diseases (1) . Epithelial-mesenchymal transition (EMT) is a central mechanism in tubulointerstitial fibrosis, in which tubular epithelial cell loss is accompanied by the deposition of extracellular matrix (ECM) and accumulation of fibroblasts and inflammatory cells in the intersitium (2) (3) (4) (5) . The phenotypic conversion of epithelial cells to myofibroblast (with expression of vimentin and less expression of E-cadherin) is the main feature of this process (6) . Increasing evidence suggests that numerous genes are involved in tubular EMT (7) (8) (9) (10) . The transforming growth factor (TGF)-β/Smad pathway is a key promoter of this process (11, 12) . Increased glomerular expression of TGF-β has been reported in experimental and human kidney disease (1, 5, 13) . Mice with increased plasma TGF-β1 levels exhibited enhanced renal fibrosis (14) . Through the induction of target genes, TGF-β signaling promotes fibroblast survival and proliferation. The range of TGF-β-target genes include microRNAs (miRNAs or miRs) (15) . miRNAs are small (21-23-nt) non-coding RNA molecules that regulate gene expression by interacting with multiple mRNAs and inducing translational suppression or degradation of mRNA (16) . miRNAs are involved in regulating diverse physiological processes ranging from embryogenesis, organ development, oncogenesis and the initial step in EMT (17) (18) (19) (23) . Therefore, approaches to correct miRNA expression represent the novel therapeutic strategies for these diseases. Homeodomain interacting protein kinase 2 (HIPK2) is a member of an evolutionary conserved family of serine/threonine kinases (24) , which is considered as a tumor suppressor gene and mediates the activation of Wnt, Notch, and TGF-β-induced signaling (25) (26) (27) . HIPK2 is also considered as a co-regulator of an increasing number of transcription factors modulating numerous different basic cellular processes, including apoptosis, proliferation, differentiation and development (24, (28) (29) (30) . Recently, HIPK2 has also been identified as a key regulator in idiopathic pulmonary fibrosis (IPF) and kidney fibrosis (31, 32) . In the kidney, HIPK2 mediates apoptosis and EMT of renal tubular epithelial cells, contributing to fibrosis. HIPK2 may be a potential target for anti-fibrosis therapy (31) . Given the ability of the miR-200 family to inhibit EMT and the evidence of HIPK2 in tissue fibrosis, whether miR-141 ameliorates tubulointerstitial fibrosis was investigated by inhibition of EMT through targeting HIPK2. In the present study, the first aim was to define a role of miR-141 in regulating EMT in TGF-β-treated human kidney 2 (HK-2) cells (normal renal tubular epithelial cells). miR-141 hindered EMT by upregulating E-cadherin and downregulating vimentin and fibroblast-specific protein 1 (FSP1) expression through direct targeting of HIPK2, by binding to its three prime untranslated region (3'-UTR).
Materials and methods
Cell lines and transfection. HK-2 cell lines were purchased from American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA, USA), 100 U/ml penicillin and 100 µg/ml streptomycin in a humidified 5% CO 2 incubator at 37˚C. Ectopic expression of miR-141 in HK-2 cells was achieved by transfection with miR-141 mimics (Genepharma, Shanghai, China) using Lipofectamine 2000 (Invitrogen). Overexpression of HIPK2 was performed using the HIPK2 ORF expression clone (GeneCopoecia, Guangzhou, China).
RNA extraction and SYBR green quantitative polymerase chain reaction (qPCR).
Total RNA was extracted using the Trizol reagent as recommended by the manufacturer (Invitrogen). RNA quality and concentration were evaluated by spectrophotometry using a NanoDrop 2000c instrument (Thermo Scientific, Rockford, IL, USA). For miRNA analysis, mature miR-141 was detected using a Hairpin-it™ miRNAs qPCR Quantitation kit (GenePharma, Shanghai, China). U6 served as an internal reference. For HIPK2 mRNA analysis, qPCR was performed using the Power SYBR-Green PCR master mix (Takara, Dalian, China) on an ABI 7900HT PCR machine (Applied Biosystems, Foster City, CA, USA), and data were normalized to β-actin and further normalized to the negative control, unless otherwise indicated. Data analysis was performed using the 2 −ΔΔCt method. Human recombinant TGF-β1 was purchased from Cell Signaling Technology (no. 8915; Danvers, MA, USA), reconstituted in 20 mM citrate (pH 3.0) at a concentration of 100 µg/ml. Further dilution was made in PBS containing 2 mg/ml albumin, stored at -20˚C for future use.
Immunoblot analysis. Whole cell lysates were collected in radioimmunoprecipitation assay buffer with protease inhibitor cocktail (Roche, Indianapolis, IN, USA). Protein concentration was measured using a bicinchoninic acid protein assay kit (Thermo Scientific). Reduced protein (10-30 µg) in Laemmli sample buffer was resolved using 6-12% sodium dodecyl sulfate polyacrylamide gel and transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). Membranes were blocked with 5% skimmed dry milk (Bio-Rad) in Tris-buffered saline (TBS) with 0.05% Tween 20 (TBST) buffer for 1 h at room temperature, incubated with primary antibody overnight at 4˚C, followed by the appropriate secondary immunoglobulin G antibody; anti-mouse, rabbit-horseradish peroxidase (Bio-Rad). Membranes were washed thoroughly between steps using TBST, and developed using the ECL Western blotting detection kit (Bio-Rad). All the primary antibodies used were from Cell Signaling Technology. The antibodies used were the following: HIPK2 (no. 5091), vimentin (no. 5741), FSP1 (no. 13018), E-cadherin (no. 3195) and β-actin (no. 4967). The blots were stripped using stripping buffer (Thermo Scientific) prior to reprobing. β-actin was used as an endogenous protein for normalization. Images were analyzed by Quantity One software (Bio-Rad).
HIPK2 3'-UTR luciferase reporter assays. The 3'-UTR for HIPK2 was PCR-amplified from genomic DNA extracted from HK-2 cells. The PCR primers used to amplify the Hipk2 3'-UTR were forward, 5'-CTCGAGACACTTTGCATAACGTATA-3'; and reverse, 5'-GCGGCCGCATTGGAACAGTAGTCAT AT-3' , whereas the primers used to amplify the mutant Hipk2 3'-UTR (with a mutant seed sequence of miR-141) were forward, 5'-TTCAAATGAATATTTCGTCTAAATAAATAAAG-3'; and reverse, 5'-TGTAGACGAAATATTCATTTGAATT TTCAAG-3'. The mutant Hipk2 3'-UTR was identical to the wild-type sequence except for the seed regions, in which the complementary sequence was used. The mutant version was generated using the Stratagene QuikChange™ site-directed mutagenesis strategy (Stratagene, La Jolla, CA, USA). Amplified 3'-UTRs were cloned downstream of the luciferase coding region in the psiCECK™-2 vector (Promega, Madison, WI, USA). The fidelity of all the constructs utilized in the study was confirmed by sequencing (ABI PRISM 377 automated sequencer; Southern Medical University, Guangzhou, Guangdong, China) and subsequent sequence alignment (NCBI BLAST) using GenBank™ accession gene ID 28996.
To assess the effect of miR-141 on reporter activity, HK-2 cells were seeded in 96-well clusters 24 h prior to transfection. The following day, medium was replaced with OptiMEM (Invitrogen), and cells were co-transfected with 100 ng reporter plasmids along with 100 ng control Rnilla-luciferase plasmid and either scrambled control miRNA (Vector) or miR141 (miR-141 Sponge) using Lipofectamine 2000 (Invitrogen).
The cells were collected 48 h post-transfection and luciferase activity was detected using a dual-luciferase reporter assay system (Promega). All the experiments were performed in triplicate, and each experiment was repeated at least three times.
Statistical analysis.
Values are shown as mean ± standard error, unless otherwise specified. SPSS 17.0 (Pearson; SPSS, Inc., Chicago, IL, USA) was used to analyze data by unpaired student t test or by analysis of variance. P<0.05 was considered to indicate a statistically significant difference.
Results

miR-141 downregulates the expression of EMT markers.
To study EMT, TGF-β1-induced EMT was used in the HK-2 cells. Exposure of HK-2 cells to TGF-β1 (2 ng/ml) for 48 h resulted in a significant decreased expression of the epithelial marker, E-cadherin, and increased expression of mesenchymal markers, vimentin and FSP1 ( (Fig. 1C) , and >50% increase of E-cadherin expression (Fig. 1D ) as compared to the control. Overall, these results indicate that miR-141 is capable of functionally disrupting the EMT switch in HK-2 cell by maintaining relative high levels of E-cadherin expression, which is consistent with previous studies reporting that the miR-200 family inhibits EMT by targeting E-cadherin transcriptional repressors (23, 34) .
TGF-β1 downregulates the expression of miR-141 accompanied by upregulation of HIPK2.
Previous published data reported that treatment with TGF-β1 lead to decreased expression of the miR-200 family, including miR-141 (33) . Therefore, qPCR analysis was used to reveal that the expression of miR-141 was significantly downregulated in HK-2 cell following TGF-β1 treatment in a dose-and time-dependent manner ( Fig. 2A and B) . The expression of miR-141 was reduced to <30% of the pretreatment level within 48 h of TGF-β1 exposure (Fig. 2B) . These results confirm that TGF-β1 treatment lead to decreased expression of miR-141.
A published systematic approach identified HIPK2 as a key regulator of renal fibrosis (31) . Another recent study implicated dysregulated HIPK2 levels in idiopathic pulmonary fibrosis (IPF) (32) . Therefore, the role of HIPK2 in TGF-β1 treated HK-2 cells was investigated. Initial qPCR demonstrated TGF-β1-mediated induction of HIPK2 in HK-2 kidney tubular cells ( Fig. 2C and D) in a dose-and time-dependent manner, which corresponded to the decreased miR-141 expression. To verify the induction of HIPK2, the expression was analyzed by western blotting in HK-2 cells. As shown in Fig. 2E and F, HK-2 cells exposed to different dose of TGF-β1 for 2 days increased the expression of HIPK2 significantly. The maximal HIPK2 mRNA and protein expression levels at 4 ng/ml TGF-β1 treatment were ~1.5-2-fold higher than the control. Furthermore, HK-2 cells exposed to TGF-β1 (2 ng/ml) for 0-3 days also increased the expression of HIPK2 significantly ( Fig. 2G and H) . This result is consistent with the observation shown in Fig. 2C and D, which means that the changes in HIPK2 expression were also observed at the protein level. Collectively, these results indicated that lower expression levels of miR-141 were significantly associated with higher levels of HIPK2 mRNA and protein expression in the same set of TGF-β1 treatment HK-2 cells.
Ectopic expression of HIPK2 promotes EMT. Dysregulation of HIPK2 has been implicated in increased proliferation, as it is typical in cancer or fibrosis (35, 36) . A recently published study identified HIPK2 as a key regulator of kidney fibrosis (31) . Whether HIPK2 was sufficient to induce EMT in the absence of TGF-β1 and what the potential role of miR-141 was during this process were investigated. Transient expression of HIPK2 ORF in HK-2 cells resulted in a considerable upregulation of HIPK2 expression to 2.0±0.2-fold ( Fig. 3A and B) accompanied by the gain of mesenchymal markers, vimentin and FSP1, and the loss expression of epithelial marker E-cadherin ( Fig. 3C;   lanes 1 and 2) . Co-transfection of miR-141 with the HIPK2 ORF clone partially restored E-cadherin expression and attenuated vimentin and FSP1 induction ( Fig. 3C; lanes 2 and 4) . These Figure 2 . TGF-β1 induces downregulation of miR-141 accompanied by up regulation of HIPK2. HK-2 cells were treated with (A) TGF-β1 (0, 1, 2 and 4 ng/ml for 2 days) or (B) TGF-β1 (2 ng/ml) for 0-3 days. The expression of miR-141 was assessed by qPCR and normalized to U6 expression. The expression for the various dose points was determined as a relative change in the absence of TGF-β1 treatment and shown as mean ± standard error (S.E). HK-2 cells were incubated with (C and E) TGF-β1 (0, 1, 2 and 4 ng/ml for 2 days) or (D and G) TGF-β1 (2 ng/ml) for 0-3 days and the HIPK2 expression level was assessed by (C and D) qPCR and (E and G) western blotting, which were consistent with the RNA expression analysis in C and D, respectively. (F and H) The results from the western analysis in E and G were quantified and subjected to densitometry and shown as a graph (P-values are compared to the control). The relative expression of HIPK2 was normalized to β-actin expression and the expression for the various dose points was determined as a relative change from dose 0 and shown as mean ± S.E. TGF, transforming growth factor; HIPK2, homeodomain-interacting protein kinase 2; qPCR, quantitative polymerase chain reaction. The western blotting results in (C) were quantified to determine whether a statistically significant difference exists between the groups and they are shown in a graph format (P<0.05 compared to the control). The intensities of the bands corresponding to vimentin, FSP1 and E-cadherin were compared to those corresponding to β-actin. The expression of EMT was determined as a relative change from miR-SCR transfected with vector and shown as mean ± standard error. HIPK2, homeodomain-interacting protein kinase 2; EMT, epithelial-mesenchymal transition; FSP1, fibroblast-specific protein 1. results are consistent with our previous results that downregulation of miR-141 is accompanied by upregulation of HIPK2 during TGF-β1-induced EMT in HK-2 cells. Therefore, downregulation of miR-141 appears to be required for mediating the upregulation of HIPK2 in the EMT process. HIPK2 can mimic the TGF-β1-induced EMT process in HK-2 cells.
miR-141 directly targets HIPK2.
The critical role of miR-141 in EMT prompted the identification of the genes that were directly regulated by miR-141. Whether overexpression of miR-141 would alter HIPK2 protein expression was initially determined. As shown in Fig. 4A and C, transfecting with miR-141 increased expression of miR-141 to ~2.3-fold, compared to the transfection of miR-SCR in the HK-2 cells. This increase in miR-141 expression decreased HIPK2 expression to an average of 50±5% in the three experiments (Fig. 4D) . Based on this observation, we hypothesize that the miR-141 inhibitor (miR-141 Sponge) should not be able to decrease HIPK2 expression. To test this hypothesis, HK-2 cells were transfected with either vector or miR-141
Sponge and HIPK2 protein expression was determined. The overexpression of miR-141 Sponge caused a downregulation of the miR-141 levels to ~0.5-fold compared to the transfection of the vector in the HK-2 cells (Fig. 4B and E) . Consequently, the decreased expression of miR-141 caused upregulation of HIPK2 expression, with an average of 1.5±0.1-fold in three experiments (Fig. 4F) . Therefore, the expression of HIPK2 was significantly decreased in miR-141-transfected cells. Taken together, TGF-β1 (Fig. 2) and miR-141 inhibitor (miR-141 Sponge) caused a similar effect on HIPK2 expression in HK-2 cells.
As miR-141 and HIPK2 3'-UTR share the same seed sequence as shown (Fig. 5A) , whether HIPK2 is the direct target of miR-141 on translational repression was further investigated. In these experiments, luciferase reporter constructs were used, incorporating a wild-type or mutant 3'-UTR of HIPK2 in which the sequence corresponding to the seed region was altered. Co-transfection of wild-type HIPK2 luciferase reporter construct or mutant 3'-UTR of HIPK2 with miR-141 or miR-SCR in HK-2 cells resulted in a significantly reduced HIPK2 3'-UTR The western blotting results in C and E were quantified to determine whether a statistically significant difference exists between the groups and are shown in a graph format (P<0.05 compared to control). The intensities of all bands corresponding to HIPK2 were compared to those corresponding to β-actin. The expression of HIPK2 was determined as a relative change from miR-SCR or vector transfection and shown as mean ± S.E. HIPK2, homeodomain-interacting protein kinase 2; qPCR, quantitative polymerase chain reaction. Figure 5 . miR-141 directly targets HIPK2 by binding to its 3'UTR. (A) Alignment of the miR-141 sequences and the putative targeted area of the 3'-UTR of human HIPK2 (http://www.targetscan.org). Also shown is the altered sequence of the mutant 3'-UTR of HIPK2. Normalized activity of luciferase reporter with the HIPK2 3'-UTR or mut-HIPK2 (1 µg) in HK-2 cells in the presence of (B) the co-transfected negative control (miR-SCR) or miR-141 (100 nmol/l), or (C) the co-transfected vector or miR-141 Sponge (100 nmol/l). Luciferase activity was measured after (B) 24 and (C) 48 h. The data are the means from a representative experiment measured in triplicate and are presented as mean ± standard error, and are shown as the ratio of firefly/Renilla luciferase activity. HIPK2, homeodomain-interacting protein kinase 2; UTR, untranslated region.
luciferase activity expression. This demonstrated that miR-141 directly repressed luciferase activity with the wild-type 3'-UTR of HIPK2 (Fig. 5B ), but not with the mutant 3'-UTR. By contrast, miR-141 Sponge increased luciferase activity with the wild-type HIPK2, but not with the mutant version of HIPK2 (Fig. 5C ).
Discussion
Tubular EMT is a series of highly-regulated pathological events, which is one of the major mechanisms leading to renal fibrosis (1, 5, 13, 37) . miRNAs are recognized to be critical regulators of a number of important developmental, homeostatic and pathogenic pathways. Recent findings suggest that miRNAs are essential for kidney development and homeostasis. The miR-200 family members were clearly downregulated in cells that had undergone EMT in response to TGF-β, and the expression of the miR-200 family alone was sufficient to prevent TGF-β-induced EMT (38) . The study by Tamagawa et al (34) demonstrated the role of miR-200c/miR-141 in the regulation of EMT and migration in head and neck squamous cell carcinoma. However, the functional involvement of miR-141 in EMT associated with tubulointerstitial fibrosis, as well as direct targeting by miR-141, has not been investigated. In the present study, miR-141 influenced the progression of TGF-β1-induced EMT in vitro. An EMT model was initially established using TGF-β1-treated HK-2 cells by observing upregulation of vimentin and FSP1 and downregulation of E-cadherin ( Fig. 1A; lanes 1 and 3) at the protein levels. Overexpression of miR-141 inhibited EMT progression in TGF-β1-treated HK-2 cells by maintaining high E-cadherin expression levels and low vimentin and FSP1 expression levels ( Fig. 1A; lanes 3 and 4) . Furthermore, miR-141 was found to be downregulated during TGF-β1-induced EMT in HK-2 cells (Fig. 2) . Given that reduced miR-141 levels are associated with increased EMT expression, and that restoring expression of miR-141 prevents EMT in HK-2 cells, miR-141 appears to play an important role in EMT, and therefore, renal fibrosis. Wang et al (33) also found that in early and more advanced models of kidney disease, the downregulation of miR-141 was also associated with increased TGF-β expression and renal scarring. Additionally, downregulated expression of miR-141 was accompanied by upregulated HIPK2 expression (Fig. 2 ). These observations suggest a possible regulatory network that drives the increased expression of HIPK2 during TGF-β1-induced EMT, perspectives that warrant further investigation.
Although a number of different factors contribute to renal fibrosis, the most known and studied profibrotic agent is TGF-β1, which is increased in the diabetic kidney (39) . Recently, HIPK2 has been also identified as a main regulator of kidney fibrosis (31) . In the kidney, HIPK2 mediates apoptosis and EMT of renal tubular epithelial cells, contributing to fibrosis (31) . In the present study, overexpression of HIPK2 resulted in the upregulation of vimentin and FSP1, and downregulation of E-cadherin (Fig. 3) , which indicates that HIPK2 mimicked TGF-β1-induced EMT in HK-2 cells. These initial studies suggested that overexpression of miR-141 inhibited TGF-β1-induced EMT (Fig. 1) . Given the possible link between miR-141 and HIPK2, whether overexpression of miR-141 hindered HIPK2 expression in HK-2 cells was investigated further. To test this hypothesis, miR-SCR or miR-141 were transfected with either vector or the HIPK2 ORF clone and the EMT markers expression was determined. The ability of miR-141 to attenuate HIPK2 expression has potential implications and may prove to be an attractive option for targeting the EMT pathway.
Certain miRs are well known to be indiscriminate and may bind to the UTR regions of a number of different genes. The results of the present study showed that overexpression of miR-141 significantly reduced the expression of HIPK2 (Fig. 4) , and therefore, it is possible that the 3'-UTR of HIPK2 may harbor a target site for miR-141. The TargetScan database indicated that HIPK2 had a target site for miR-141, as shown in Fig. 5A . In the study, miR-141 was shown to be a direct repressor of HIPK2 as it targeted the 3'-UTR of this gene, as shown by experiments using the wild-type and mutant HIPK2 3'-UTR-luciferase constructs. HIPK2 was a transcriptional cofactor in the downstream TGF-β/BMP signaling pathway (27, 31, (40) (41) (42) . Notably, loss of HIPK2 reduced cellular responses to TGF-β during neuronal development and in mouse models of renal fibrosis (27, 40) . In addition, the present experimental results confirmed that HIPK2 was a functional target of miR-141 in HK-2 cells. There are several lines of evidence to support this. Firstly, protein expression of HIPK2 was significantly decreased in the miR-141 group compared to the miR-SCR group (Fig. 4) . Overexpression of miR-141 significantly downregulated HIPK2 by directly targeting the 3'UTR of HIPK2 mRNA, confirmed using the luciferase reporter-gene assays (Fig. 5) . This effect was largely eliminated when the sites in HIPK2 3'UTR targeted by miR-141 were mutated. Overexpression of HIPK2 mimicked TGF-β1-induced EMT, and overexpression of miR-141 rescued the expression of epithelial marker E-cadherin and inhibited HIPK2-induced EMT ( Fig. 3C and F; lanes 3 and 4) . These results strongly suggested that miR-141, through directly targeting of HIPK2, Figure 6 . Schematic model depicting that miR-141 controls EMT markers via repression of HIPK2 expression in HK-2 cells based on the data of the present study. TGF-β1 downregulated the expression of miR-141, upregulated the expression of HIPK2, and consequently regulated the EMT markers in HK-2 cells. Simultaneously, miR-141 targeted HIPK2 to regulate the protein expression of the EMT markers (vimentin, FSP1 and E-cadherin). The process plays an important role in the formation of renal fibrosis. EMT, epithelial-mesenchymal transition; HIPK2, homeodomain-interacting protein kinase 2; TGF, transforming growth factor; FSP1, fibroblast-specific protein 1. plays an essential role in renal proximal tubular EMT. miR-141 suppresses the expression of HIPK2 through directly interacting with its wild-type 3'-UTR.
In the present study, ectopic expression of miR-141 hindered the progression of EMT in TGF-β1-treated HK-2 cells by downregulation of HIPK2 expression, maintaining a high expression level of E-cadherin. Since HIPK2 has been indicated to be involved in the progression of EMT by suppression of E-cadherin expression, it may provide important targets for therapeutic strategies. The findings in the study suggested that miR-141 was downregulated in TGF-β1-treated HK-2 cells. This not only reveals a close association between the miR-141 expression level and epithelial phenotypic conversion, but also implicates a potential role of miR-141 in the regulation of tubular dedifferentiation, which is a frequent pathogenesis in tubular interstitial fibrosis in a number of types of chronic kidney disease. Evidently, more studies are required to further characterize the role of miR-141 in the pathogenesis of EMT, as well as to depict detailed molecular pathways that are involved in EMT and kidney fibrosis following chronic renal injury.
In conclusion, the present results indicate that miR-141 coordinately regulates the TGF-β1-induced EMT process through the HIPK2 signaling pathway (Fig. 6 ) and exogenous overexpression of miR-141 may represent a promising approach for targeted kidney fibriosis therapies.
